Abkyu Enters Strategic Discovery Agreement with Synap Bio to Identify and Develop Novel VHH Clinical Assets
WATERTOWN, Mass., June 22, 2026 — Abkyu, Inc. today announced a strategic discovery agreement with Synap Biotech under which Synap will nominate therapeutic targets and Abkyu will apply its proprietary VHH discovery platform to identify, engineer, and develop the resulting clinical assets. The arrangement is designed to give Synap a direct pipeline into Abkyu’s discovery […]
Abkyu and Artemia Therapeutics Announce Strategic VHH Discovery Partnership
WATERTOWN, Mass., May 21, 2026 — Abkyu, Inc., a biotechnology company specializing in single-domain antibody (VHH) discovery, today announced it has entered into a strategic discovery partnership with Artemia Therapeutics, Inc., a biotechnology company developing multi-specific T-cell engagers for autoimmune diseases and oncology, to discover and develop novel VHH candidates for their therapeutic programs. The […]
Abkyu and Jeevan Therapeutics Announce Strategic VHH Discovery Agreement
WATERTOWN, Mass., September 2, 2025 — Abkyu, Inc., a biotechnology company specializing in single-domain antibody (VHH) discovery, today announced a strategic discovery partnership with Jeevan Therapeutics, a biotechnology company founded by experienced industry leaders in biologics and small molecule development. The collaboration, valued at up to $200 million, will leverage Abkyu’s proprietary VHH discovery platform […]